Genetic polymorphism of organic cation transporter 2 (OCT2) and its effects on the pharmacokinetics and pharmacodynamics of Metformin: a narrative review
Abstract Background Organic cation transporter 2 (OCT2) is a renal carrier transporter protein found in the basolateral membrane of proximal epithelial cells, which facilitates active secretion of Metformin. The genetic polymorphism of OCT2 influences the pharmacodynamic and pharmacokinetic effect o...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2023-01-01
|
| Series: | Egyptian Journal of Medical Human Genetics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43042-023-00388-z |
| _version_ | 1811175843925327872 |
|---|---|
| author | Swathi Swaroopa Borra Niva Rose Jane Dhivyaprasath Palaniappan Rupakrishnan Subramanian Mithila Amar Patankar Sadagoban Gopal Krishnamoorthy Arun Kanniyappan Parthasarathy |
| author_facet | Swathi Swaroopa Borra Niva Rose Jane Dhivyaprasath Palaniappan Rupakrishnan Subramanian Mithila Amar Patankar Sadagoban Gopal Krishnamoorthy Arun Kanniyappan Parthasarathy |
| author_sort | Swathi Swaroopa Borra |
| collection | DOAJ |
| description | Abstract Background Organic cation transporter 2 (OCT2) is a renal carrier transporter protein found in the basolateral membrane of proximal epithelial cells, which facilitates active secretion of Metformin. The genetic polymorphism of OCT2 influences the pharmacodynamic and pharmacokinetic effect of Metformin in type 2 diabetes mellitus (T2DM) patients. This is also mainly associated with frequencies of the associated risk allele in a particular population. Objective The purpose of the study is to determine the impact of OCT2 genetic polymorphism on Metformin pharmacodynamics (PD) and pharmacokinetics (PK). Method of study Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used for performing the research. Following databases were used to conduct the search: PubMed/MEDLINE, Google Scholar, and the Cochrane Library. Relevant studies were retrieved and literatures were appraised for methodology, demographic characteristics, relevant SNPs, genetic intervention trials, and outcomes. Results Based on the data collected, 13 OCT2 Single nucleotide polymorphisms (SNPs) were identified across various ethnic groups. There were significant differences between the frequency distribution of shared alleles and impact of thirteen SNPs on Metformin. Among the thirteen OCT2 variants studied, rs316019 variant produced the most diverse responses in population by showing positive and negative impact on PK & PD of Metformin. Discussion and conclusion Each population's OCT2 polymorphism had a distinct effect on Metformin responsiveness. The findings of this study could bring significant benefits to patients with OCT2 genetic polymorphism if individualised T2DM therapy is introduced. Patient-centered treatment would improve the Metformin efficacy leading to new research in personalised medicine. |
| first_indexed | 2024-04-10T19:43:37Z |
| format | Article |
| id | doaj.art-eec71801638b4d83a62fd429a0104aaf |
| institution | Directory Open Access Journal |
| issn | 2090-2441 |
| language | English |
| last_indexed | 2024-04-10T19:43:37Z |
| publishDate | 2023-01-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Egyptian Journal of Medical Human Genetics |
| spelling | doaj.art-eec71801638b4d83a62fd429a0104aaf2023-01-29T12:14:04ZengSpringerOpenEgyptian Journal of Medical Human Genetics2090-24412023-01-012411910.1186/s43042-023-00388-zGenetic polymorphism of organic cation transporter 2 (OCT2) and its effects on the pharmacokinetics and pharmacodynamics of Metformin: a narrative reviewSwathi Swaroopa Borra0Niva Rose Jane1Dhivyaprasath Palaniappan2Rupakrishnan Subramanian3Mithila Amar Patankar4Sadagoban Gopal Krishnamoorthy5Arun Kanniyappan Parthasarathy6Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and ResearchDepartment of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and ResearchDepartment of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and ResearchDepartment of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and ResearchDepartment of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and ResearchDepartment of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and ResearchDepartment of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and ResearchAbstract Background Organic cation transporter 2 (OCT2) is a renal carrier transporter protein found in the basolateral membrane of proximal epithelial cells, which facilitates active secretion of Metformin. The genetic polymorphism of OCT2 influences the pharmacodynamic and pharmacokinetic effect of Metformin in type 2 diabetes mellitus (T2DM) patients. This is also mainly associated with frequencies of the associated risk allele in a particular population. Objective The purpose of the study is to determine the impact of OCT2 genetic polymorphism on Metformin pharmacodynamics (PD) and pharmacokinetics (PK). Method of study Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used for performing the research. Following databases were used to conduct the search: PubMed/MEDLINE, Google Scholar, and the Cochrane Library. Relevant studies were retrieved and literatures were appraised for methodology, demographic characteristics, relevant SNPs, genetic intervention trials, and outcomes. Results Based on the data collected, 13 OCT2 Single nucleotide polymorphisms (SNPs) were identified across various ethnic groups. There were significant differences between the frequency distribution of shared alleles and impact of thirteen SNPs on Metformin. Among the thirteen OCT2 variants studied, rs316019 variant produced the most diverse responses in population by showing positive and negative impact on PK & PD of Metformin. Discussion and conclusion Each population's OCT2 polymorphism had a distinct effect on Metformin responsiveness. The findings of this study could bring significant benefits to patients with OCT2 genetic polymorphism if individualised T2DM therapy is introduced. Patient-centered treatment would improve the Metformin efficacy leading to new research in personalised medicine.https://doi.org/10.1186/s43042-023-00388-zGenetic polymorphismOCT2SLC22A2Substrate drugsMetforminType 2 diabetes mellitus (T2DM) |
| spellingShingle | Swathi Swaroopa Borra Niva Rose Jane Dhivyaprasath Palaniappan Rupakrishnan Subramanian Mithila Amar Patankar Sadagoban Gopal Krishnamoorthy Arun Kanniyappan Parthasarathy Genetic polymorphism of organic cation transporter 2 (OCT2) and its effects on the pharmacokinetics and pharmacodynamics of Metformin: a narrative review Egyptian Journal of Medical Human Genetics Genetic polymorphism OCT2 SLC22A2 Substrate drugs Metformin Type 2 diabetes mellitus (T2DM) |
| title | Genetic polymorphism of organic cation transporter 2 (OCT2) and its effects on the pharmacokinetics and pharmacodynamics of Metformin: a narrative review |
| title_full | Genetic polymorphism of organic cation transporter 2 (OCT2) and its effects on the pharmacokinetics and pharmacodynamics of Metformin: a narrative review |
| title_fullStr | Genetic polymorphism of organic cation transporter 2 (OCT2) and its effects on the pharmacokinetics and pharmacodynamics of Metformin: a narrative review |
| title_full_unstemmed | Genetic polymorphism of organic cation transporter 2 (OCT2) and its effects on the pharmacokinetics and pharmacodynamics of Metformin: a narrative review |
| title_short | Genetic polymorphism of organic cation transporter 2 (OCT2) and its effects on the pharmacokinetics and pharmacodynamics of Metformin: a narrative review |
| title_sort | genetic polymorphism of organic cation transporter 2 oct2 and its effects on the pharmacokinetics and pharmacodynamics of metformin a narrative review |
| topic | Genetic polymorphism OCT2 SLC22A2 Substrate drugs Metformin Type 2 diabetes mellitus (T2DM) |
| url | https://doi.org/10.1186/s43042-023-00388-z |
| work_keys_str_mv | AT swathiswaroopaborra geneticpolymorphismoforganiccationtransporter2oct2anditseffectsonthepharmacokineticsandpharmacodynamicsofmetforminanarrativereview AT nivarosejane geneticpolymorphismoforganiccationtransporter2oct2anditseffectsonthepharmacokineticsandpharmacodynamicsofmetforminanarrativereview AT dhivyaprasathpalaniappan geneticpolymorphismoforganiccationtransporter2oct2anditseffectsonthepharmacokineticsandpharmacodynamicsofmetforminanarrativereview AT rupakrishnansubramanian geneticpolymorphismoforganiccationtransporter2oct2anditseffectsonthepharmacokineticsandpharmacodynamicsofmetforminanarrativereview AT mithilaamarpatankar geneticpolymorphismoforganiccationtransporter2oct2anditseffectsonthepharmacokineticsandpharmacodynamicsofmetforminanarrativereview AT sadagobangopalkrishnamoorthy geneticpolymorphismoforganiccationtransporter2oct2anditseffectsonthepharmacokineticsandpharmacodynamicsofmetforminanarrativereview AT arunkanniyappanparthasarathy geneticpolymorphismoforganiccationtransporter2oct2anditseffectsonthepharmacokineticsandpharmacodynamicsofmetforminanarrativereview |